NCT04335383View on ClinicalTrials.gov

Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies

RecruitingOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

October 5, 2020

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Pseudomonas AeruginosaMulti-antibiotic Resistance
Interventions
BIOLOGICAL

Isolation of anti-Pseudomonas antibodies from type B lymphocytes

Blood sampling. Isolation of mononuclear cells from human peripheral blood by density gradient centrifugation. Identification of functional anti-Pseudomonas antibodies by ELISA and cellular infection assays.

Trial Locations (1)

38043

RECRUITING

Chu Grenoble Alpes, Grenoble

All Listed Sponsors
lead

University Hospital, Grenoble

OTHER

NCT04335383 - Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies | Biotech Hunter | Biotech Hunter